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Abstract: Long-term opioid therapy may be associated with analgesic efficacy and also pre-
dictable adverse events, including cardiovascular and pulmonary events, gastrointestinal disorders,
endocrinological harms, psychological problems, impairment of driving ability, and risk of abuse.
These effects of opioids are mostly due to the wide expression of the mu receptor. Tapentadol,
a centrally acting analgesic, is the first agent of a new class of drugs (MOR-NRI), since it combines
two mechanisms of action, namely µ-opioid receptor (MOR) agonism and noradrenaline reuptake
inhibition. Noteworthy, MOR activation with tapentadol is markedly lower compared with that
exerted by classical opioids, thus likely resulting in fewer opioid-related adverse effects. In this
review, we discuss current safety data on tapentadol, with a focus on some specific events, risk of
abuse, and driving ability, a well-accepted proxy of the ability of taking critical decisions.
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Introduction
Opioids are a recognized analgesic treatment, used in clinical practice to manage
both acute and chronic pain conditions.1,2 However, long-term opioid therapy may
be associated with a number of adverse events (AEs), including cardiovascular and
pulmonary events, gastrointestinal disorders, endocrinological harms, psychological
problems, and risk of abuse; those events are frequently observed from the very
beginning of therapy.1,3 Moreover, well-grounded evidence shows that opioid use
may be associated with an increased risk of vehicle crashes, a surrogate for safety-
sensitive work and decision tasks.3 The abovementioned effects of opioids are due
to the wide expression of the mu receptor.4
Tapentadol, a centrally acting analgesic, has been suggested to be the first agent
of a new class of drugs (MOR-NRI).5,6 It combines two mechanisms of action,
namely µ-opioid receptor (MOR) agonism and noradrenaline reuptake inhibition
(NRI), thus providing a strong analgesic effect by a synergic action.7 Indeed,
traditional opioids (eg, morphine, oxycodone) exert their analgesic effects primarily
through a single mechanism—MOR activation.8 Therefore, the contribution of the
opioid component to adverse effects is 100%. In contrast, tapentadol produces its
analgesic effect via two separate and complementary analgesic mechanisms, only
one of which is targeting MOR, and the other NRI. Remarkably, this last compo-
nent of tapentadol action can be inhibited by NRI blockers.9 Moreover, the admin-
istration of opioid antagonist like naloxone does not inhibit tapentadol efficacy, thus
further supporting the double mechanism of action of this molecule.10,11
Experimental evidence supporting that NRI is a key mechanism (descending
modulating spinal pathway) that can be predominant in chronic/neuropathic pain,
reinforces the concept that tapentadol is different to classical opioids and may
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therefore be an a priori choice for the treatment of chronic,
neuropathic and mixed pain.12
This concept has been strengthened and expanded to other
drugs byRaffa and Pergolizzi; they state that the categorization
of all analgesics that have any component of opioidmechanism
of action into the same class is anachronistic and
misleading.8,13 Noteworthy, MOR activation with tapentadol
is markedly lower compared with that exerted by classical
opioids, thus likely resulting in fewer opioid-related AEs.14
In this line, a very recent study suggested that the “µ-load”
(the percentage contribution of the opioid component to the
adverse effectmagnitude relative to a pure/classical µ-opioid at
equianalgesia) of tapentadol is ≤40% with respect to pure
MOR agonists; this reduced µ-load may translate into a more
favorable tolerability profile compared with strong opioids.13
Indeed, it has been shown that the different pharmacological
effects of tapentadol are not synergic in terms of AEs.15,16
In this narrative review, we discuss current safety data
on tapentadol, with a focus on some specific events, risk of
abuse and effects on driving ability.
Overview of safety profile
A very recent comprehensive review by Stollenwerk et al has
extensively discussed the tolerability profile of tapentadol on
the bases of published studies (n=12,506) and “field-practice”
post-marketing data from several databases, including some of
Grunenthal (the manufacturer of tapentadol) property
(n=10,689).14 Overall, 7,185 subjects in clinical trials (57.5%)
and 777 patients included in “field-practice” databases (7.3%)
experienced tapentadol-related AEs, for a total of 18,028
events. µ-receptor-dependent events, such as gastrointestinal,
and CNS-related drug reactions were the most frequent. On the
other hand, noradrenergic-dependent reactions were negligible.
The tolerability profile was similar in the elderly and younger
populations.14 This latter finding is in line with the results of
a study by Biondi et al, who conducted a pooled post hoc
analysis from three trials specifically comparing tapentadol
prolonged release (PR) and oxycodone controlled release
(CR) in patients aged ≥75 years with moderate-to-severe,
chronic osteoarthritis knee or low back pain.17 Overall, the
incidence of gastrointestinal treatment-emergent AEs and
vomiting and the composite of nausea and/or vomiting were
significantly lower in the tapentadol PR group (all p≤0.0206).
It is also worth noticing that the long-term safety of
tapentadol has been confirmed in several studies,18,19 with
specific data collected in a study over a 4-year period.20
Toxicities of special interest
Gastrointestinal effects
Constipation is a well-known side effect of opioid ther-
apy. In recent years, some studies have evaluated the
impact of tapentadol on constipation when compared
with traditional opioids.
In 2011, Kwong et al examined patient-reported bowel
function during two trials on the immediate release (IR)
formulation of tapentadol versus placebo and oxycodone
IR.21 Bowel function was comparable between patients on
tapentadol IR and those on placebo, and better versus
oxycodone IR, both over a short- and long-term period;
similar findings were reported for PAC-SYM summary
scores collected over a longer term; the use of laxatives
was also lower with tapentadol IR.
The low incidence of gastrointestinal AEs with tapentadol
was confirmed in post hoc meta-analysis of three randomized,
multicenter, double-blind trials on tapentadol extended release
(ER).22 Patients affected from moderate-to-severe chronic
osteoarthritis knee pain or low back pain treated by either
tapentadol ER (n=978) or oxycodone CR (n=999) were inves-
tigated. The primary endpoint was a ≥30% pain relief without
nausea/vomiting/constipation and without discontinuations
(≥30% pain relief/tolerability). After 12 weeks of treatment,
patients on tapentadol PR were more likely to have ≥30% than
oxycodone CR recipients (OR, 3.15; 95% CI: 2.47–4.00;
p<0.001), and the achievement of this endpoint was associated
with improved quality of life (QoL). Thesefindings suggest that
tapentadol ER was associated with significantly better compo-
site outcomes than oxycodone CR.
Similar results were achieved in a pooled analysis of data
from four Phase III studies.23 Patients affected from moderate-
to-severe chronic osteoarthritis hip and knee pain or low back
pain assigned to placebo (n=993), tapentadol PR (n=1874) or
oxycodone CR (n=1224) were investigated. In the placebo,
tapentadol PR and oxycodone CR groups, the incidence of
gastrointestinal AEs was 26.6% (264/993), 47.3% (887/
1,874), and 65.4% (800/1,224), respectively. In the placebo,
tapentadol PR, and oxycodone CR groups, moderate or severe
constipation was reported in 2.4% (24/993), 8.6% (161/1,874),
and 18.5% (226/1,224) of patients, respectively. The superiority
of tapentadol PR over oxycodone CR was also reported about
other gastrointestinal AEs such as moderate-to-severe nausea
and vomiting. These findings were also confirmed in a more
recentmeta-analysis of two double-blind, randomized, placebo-
, and oxycodone CR-controlled Phase III trials enrolling a total
of 1,357 patients.24 Overall, compared with oxycodone CR, the
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gastrointestinal tolerability was better with, regardless of
patients’ age.
Despite these favorable results in a meta-analysis of
nine studies with ≥4 weeks’ duration on 4,159 patients
with non-cancer pain lasting at least 3 months, the pooled
analysis on the subgroup of patients with osteoarthritis
pain showed no difference between tapentadol PR and
oxycodone CR in terms of tolerability.25 Unfortunately,
tolerability was analyzed only in terms of generic with-
drawal because of AEs and not considering specific out-
comes of gastrointestinal tolerability, such as constipation,
nausea, and vomiting. Afterward, superiority of tapentadol
PR over oxycodone CR about gastrointestinal tolerability,
especially in terms of constipation, nausea, and vomiting,
was demonstrated in other studies.26,27
While superiority of tapentadol PR over oxycodone CR
in terms of gastrointestinal tolerability can be considered
as well established, somehow conflicting results seems to
emerge from the literature with regards to the comparison
with the oxycodone/naloxone PR combination. However,
data supporting the gastrointestinal safety of tapentadol PR
were collected in studies with a more rigorous design.
Indeed, a systematic review by Thakur et al analyzed
the impact of oxycodone/naloxone PR on daily function-
ing in comparison with tapentadol PR in adult patients
with moderate-to-severe chronic cancer and non-cancer.28
Gastrointestinal AEs (including constipation) in this sys-
tematic review demonstrated no statistically significant
different incidences between tapentadol PR and oxyco-
done/naloxone PR. However, this study was affected by
severe limitations, including a higher level of baseline pain
severity in the tapentadol group and some methodological
issues.29
Baron et al compared tapentadol PR versus oxycodone/
naloxone PR in patients with severe chronic low back pain
with a neuropathic component.30 Tapentadol PR was non-
inferior to oxycodone/naloxone PR from baseline to final
evaluation. In addition, tapentadol PR was associated with
significantly lower incidences of constipation and vomit-
ing than oxycodone/naloxone PR during both the titration
and overall treatment periods, as well as a significantly
lower incidence of mild, moderate or severe nausea,
vomiting, or constipation during the titration period.
Ueberall et al evaluated efficacy and tolerability of oxyco-
done/naloxone PR in comparison with tapentadol PR by data
randomly extracted from German Pain Registry on adult
patients with chronic low back pain with neuropathic
component.31 Constipation was assessed using bowel function
index (BFI) at the end of each treatment week. BFI scores
increased from baseline to the end of the observation from
14.9±15.5 to 18.0±15.5 (p<0.001) with tapentadol PR and
from 16.7±17.1 to 23.2±17.6 (p<0.001) with oxycodone/
naloxone PR. Percentages of patients with BFI scores within
the normal range (ie, ≤28.8) at the end of observation were
72.2% (96/133) for tapentadol PR and 68.0% (87/128) for
oxycodone/naloxone PR (p=0.457). Regarding the incidence
of gastrointestinal AEs, no statistically difference was regis-
tered on nausea, vomiting, abdominal pain and constipation;
this finding can be attributed, at least in part, to the inherent
limitations of the study design.31–33 However, constipation
affected six patients taking oxycodone/naloxone PR and only
one patient taking tapentadol PR, nearly achieving statistical
significance.
Tapentadol PR and oxycodone/naloxone PR were recently
compared also in the field of postoperative pain treatment in
orthopedic trauma surgery by Haeseler et al.34 In this rando-
mized, observer-blinded, active-controlled prospective clinical
trial, gastrointestinal AEs showed no statistically difference
between the two drugs. In particularly, constipation occurred
during observation in 35% of the tapentadol PR patients and in
30% of the oxycodone/naloxone PR patients while vomiting
occurred in 3% of the tapentadol PR patients and in 8% of the
oxycodone/naloxone PR patients.
Finally, a recent Australian report by Abeyaratne et al
focuses on AEs related to tapentadol PR and oxycodone/
naloxone PR treatment.35 The public case reports were
extracted from the Australian Therapeutic Goods
Administration for tapentadol PR (104 reports) and
April 2011–March 2017 for oxycodone/naloxone PR (249
reports). Regarding gastrointestinal AEs, this observation
revealed 18 reports for tapentadol PR (17.3%) and 73 for
oxycodone/naloxone PR (29.3%). Interestingly, constipation
is not reported in detail as AEs for both drugs, while most of
the reported gastrointestinal AEs were nausea, abdominal pain
and diarrhea.
Hypertension
Hypertension is one of the most frequent co-existing
conditions in patients with chronic pain; therefore, the
potential effects of analgesic therapy on heart rate and
blood pressure are a major concern in patients with this
condition. Biondi et al specifically investigated changes
in blood pressure and heart rate with tapentadol PR in
a large population (n=1464) of patients with hyperten-
sion enrolled in three Phase III trials comparing tapen-
tadol with placebo and oxycodone CR.36 Overall, least-
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squares mean changes from baseline to 15 weeks for
heart rate with placebo, tapentadol PR, and oxycodone
were −0.7 (0.44), 0.2 (0.43), and −0.9 (0.45) bpm.
Corresponding figures for systolic blood pressure were
−2.4 (0.64), −2.7 (0.64), and −3.7 (0.67) mmHg; and
−1.0 (0.39), −1.3 (0.39), and −2.3 (0.41) mmHg for
diastolic blood pressure. No clinically meaningful
mean changes in heart rate or blood pressure were
observed for the evaluated cohorts of patients with
hypertension who were treated with tapentadol ER
(100–250 mg twice daily). These findings were also
consistent when only patients on anti-hypertensive treat-
ment were analyzed. Available data demonstrate that
tapentadol has a good cardiovascular safety profile.
Pulmonary function
In a recent randomized, cross-over, placebo-controlled study
on 15 healthy volunteers, Van der Schrier et al compared the
respiratory effects of tapentadol 100–150 mg with those of
oxycodone 20 mg.37 The main endpoint was the effect of
treatment on the ventilatory response to hypercapnia and
ventilation at an extrapolated end-tidal CO2 of 55 mmHg
(VE55). Overall, oxycodone 20 mg determined
a significantly greater respiratory depressant effect than tapen-
tadol 100 mg (mean difference −5.0 L min−1, 95% CI: −7.1 to
−2.9 L min−1, p<0.01). Therefore, tapentadol has a lower
impact than a μ-pure agonist opioid on respiratory function,
probably due to its low µ-load.8
Serotonin syndrome
Serotonin syndrome is a collective term for a spectrum
of serotonergic adverse reactions that result from over-
activation of both central and peripheral serotonin recep-
tors due to increased serotonin levels. This syndrome is
characterized by neuromuscular and autonomic hyperac-
tivity, and altered mental status. In the comprehensive
analysis of tapentadol-associated AEs by Stollenwerk,12
there were no reports of correctly diagnosed – namely
by the Hunter criteria38 – serotonin syndrome with
tapentadol in clinical trials and only one case in “field-
practice” databases. ICT database of Phase II, III, and
IV prospective trials report only one case in the NIT
database, occurred in a patient on concomitant seroto-
nergic medication. Remarkably, the SmPC of tapentadol
has been changed to better define serotonin syndrome
according to the Hunter criteria, and avoid false
reporting.
The recent Australian report by Abeyaratne et al on
adverse drug events related to tapentadol PR treatment showed
52 patients on 104 (50%) reporting nervous system disorders,
16 of which suffering from serotonin syndrome (23.2%).35 In
14 of 16 patients, the concomitant use of one or more seroto-
nergic agents (tramadol, duloxetine, venlafaxine, amitripty-
line, sertraline, desvenlafaxine, escitalopram) was reported.
Gressler et al in a systematic review of the literature concluded
that the currently available data do not allow to find or to
exclude a correlation between tapentadol and serotonin
syndrome.39,40
Endocrine-related toxicity
Opioid-induced androgen deficiency (OPIAD) is commonly
reported in association with opioid therapy.41,42 Noteworthy, it
has been suggested that drugs characterized by dual activity,
such as tapentadol, may be associated with a more favorable
pattern of endocrine-related toxicity.42 Eichenbaum et al eval-
uated the effects of tapentadol in healthy male volunteers
versus placebo and morphine and in patients with osteoarthri-
tis, compared with placebo and oxycodone.41 In addition, they
conducted three randomized, double-blind, placebo-controlled
clinical studies: a single-dose comparison study of tapentadol
IR versus morphine in healthy volunteers, a single dose-
escalation study in healthy volunteers without an active com-
parator, and a multiple-dose study versus oxycodone CR in
patients with osteoarthritis. In the first study, serum total tes-
tosterone concentrations were similar at baseline for all treat-
ment periods; 6 hrs after dosing, mean concentrations were
comparable between placebo (8.6 nmol/L) and tapentadol IR
(9.3 nmol/L) but were lower after the administration of mor-
phine IR 30 mg (5.4 nmol/L). Similar results were reported in
the second study (tapentadol IR vs placebo). In the third trial,
decrease in testosterone concentration from baseline for
patients on tapentadol PR (100 mg, −1.9 nmol/L; 200 mg,
−2.1 nmol/L) was numerically smaller than with oxycodone
CR (−2.7 nmol/L), but higher compared with placebo (−0.3
nmol/L).
In a landmark study,Baron et al compared the effectiveness
of tapentadol PR versus oxycodone/naloxone PR in opioid-
naive patients with severe chronic low back pain with
a neuropathic pain component.30 The effects of these analgesic
therapies on the concentration of testosterone were specifically
investigated in male patients aged ≤64 years enrolled in that
study who had normal baseline testosterone levels and had
completed the opioid treatment. In the tapentadol group, the
average testosterone concentration did not change from base-
line to final evaluation, while a significant decrease in the
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average testosterone concentration was observed with oxyco-
done/naloxone. Furthermore, a higher percentage of these
patients had a low testosterone concentration (<8.4 nmol/L)
in the oxycodone/naloxone PR group than in the tapentadol
PR.30 Therefore, available data suggest that tapentadol has
a minimal or no impact on testosterone levels and on OPIAD.
Convulsion
Chronic use of opioids in neuropathic pain has been the
subject of numerous critical analysis and the relationship
between the therapeutic effect and the side effects (particu-
larly on the abuse potential) has been widely debated.
Convulsions are a known effect of opioid therapy, likely
due to the inhibition of hippocampal gamma-aminobutyric
acid release by interneurons, which leads to excitatory
effects.14 However, most opioid convulsions are observed
only at dosages higher than those commonly used in clinical
practice. In the comprehensive analysis of tapentadol safety
by Stollenwerk et al,14 there were no reports of convulsion
in clinical trials or of seizures in “field-practice” studies.
Risk of abuse
An unintended, but frequent, consequence of prescribing
opioid analgesics is represented by abuse and diversion of
these medications.43 In 2012, Dart et al estimated abuse
and diversion rates for tapentadol IR compared with oxy-
codone, hydrocodone, and tramadol, by analyzing the
RADARS® database.43 Overall, during the 24 months
immediately following its introduction, tapentadol was
associated with very limited rates of abuse and diversion.
These findings are in line with those of a more recent
study but require further analyses before definite conclu-
sions can be reached.44
Driving
Some studies evaluating the efficacy and safety of therapeutic
opioids report that patients on stable doses of opioid analgesics
may be able to drive safely based on individual evaluation.45–
47 However, several medications, including opioid analgesics,
are associated with an increased risk of motor vehicle collision
and decreased driving ability.48,49 Medications with MOR
activity may adversely affect Tapentadol, in a randomized,
controlled Phase III study,50 was associated with a lower
incidence of dizziness and fewer discontinuations due to ner-
vous system adverse effects than oxycodone CR. Based on
these considerations, Sabatowski et al conducted
a multicenter, open-label, Phase IIIb trial with the aim of
evaluating the effects of tapentadol PR on driving ability.49
In total, 36 patients who had completed previous tapentadol
PR trials for severe low back or osteoarthritis pain were
evaluated; after ≥6 weeks on a stable dose of tapentadol PR,
patients continued treatment (50–250 mg twice daily) and
could take tapentadol 50 mg IR, except on the day before
or day of the driving test (before the test). The Vienna Test
System-Traffic Plus was used to assess cognitive and psycho-
motor function, and other battery tests were employed to
evaluate driving ability. Overall, approximately two-thirds
(65.7%) of the patients were deemed to be fit to drive based
on the global judgment of driving-specific ability. Total daily
tapentadol PR dose (>200 vs ≤200 mg/day) did not affect the
evaluation of driving ability.
Although not specifically related to driving, a very
recent study on a small number of subjects (n=24, of
whom 12 were healthy volunteers) suggested a potential
impairment in movement variability during treadmill
walking with tapentadol.51 These findings are to be con-
sidered not conclusive so far, and should be investigated in
larger studies.
Conclusion
The safety of a drug is a particularly important aspect in
chronic therapies, in comorbid patients and in the more sensi-
tive age groups, such as elderly and children (the European
Medicines Agency has recently approved a pediatric formula-
tion of tapentadol, on the basis of its safety in this
population).52 Long-term treatment with opioids can be asso-
ciated with several AEs, also of major severity, risk of abuse
and impaired ability to take critical decisions. These effects are
largely due to the wide expression of the µ receptor in the
different organs and apparatuses.
Therefore, a drug characterized by a dual mechanism of
action, such as tapentadol, may exert an effective analgesia
while sparing from opioid-related AEs. Indeed, the large
experience collected in clinical trials and in “field-practice”
studies does support the good tolerability profile of tapenta-
dol. Importantly, safety data for this drug extend up to
4 years, a follow-up period longer than other opioids: in
a recent Cochrane meta-analysis on opioids for non-cancer
pain, the longest study was 13 months in duration.1 Over this
observation period, no serious or unexpected AEs occurred
during treatment with tapentadol.
Tapentadol appeared also to be better tolerated compared
with opioids in studies evaluating specific AEs, such as gastro-
intestinal events, hypertension, pulmonary dysfunction, sero-
tonin syndrome, endocrine toxicity – important for young and
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adult patients – convulsions. Although some of these studies
were limited in sample size, they were designed with the aim
to investigate the abovementioned events and therefore may
provide well-grounded evidence on the safety of tapentadol.
Remarkably, a favorable tolerability profile over
a long-term period is a key determinant of treatment selec-
tion in clinical practice, as it can be associated with main-
tenance of QoL and improved compliance. We believe that
the available safety data on tapentadol PR, together with
its marked analgesic efficacy, support the use of this drug
for the treatment of chronic painful conditions.
Key points
● The safety of a drug is a particularly important aspect
in chronic therapies.
● Long-term treatment with opioid can be associated
with several AEs, also of major severity, risk of
abuse and impaired ability to take critical decisions.
These effects are largely due to the wide expression
of the µ receptor in various body system and
apparatus.
● Therefore, a molecule characterized by a dual mechan-
ism of action, like tapentadol, with a moderate affinity
for different receptors may exert effective analgesia
while sparing from opioid-related AEs.
● Safety data for tapentadol extend up to 4 years,
a follow-up longer than for opioids. Over this obser-
vation period, no serious or unexpected AEs occurred
during treatment with tapentadol
● Tapentadol also appeared better tolerated than
opioids in studies evaluating specific AEs, such as
gastrointestinal events, hypertension, pulmonary dys-
function, serotonin syndrome, endocrine toxicity, and
convulsions.
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